title: Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode.
abstract: OBJECTIVE
  We compared the level of plasma D-dimer in patients with previous venous thromboembolism (VTE), receiving or not oral anticoagulant treatment (OAT) and investigated its predictive value for the risk of VTE recurrence after OAT withdrawal.
  
  
  METHODS
  We have studied 149 patients, 81 receiving oral anticoagulants and 68 after treatment interruption. Patients with known causes of D-dimer increase were excluded. D-dimer measurements were performed by Vidas analyzer (bioMérieux, France).
  
  
  RESULTS
  A significantly lower D-dimer plasma level was found in patients under OAT than in untreated patients, 197+/-134 ng/ml versus 399+/-239 ng/ml, respectively (p<0.001). This decrease was similar in the different age populations and whether the patient had thrombophilia (n=84) or not. There was no correlation between INR and D-dimer levels. During a mean follow-up of 30 months, no recurrence occurred in patients under OAT versus 7 untreated patients. Among them, 3 had a D-dimer below 500 ng/ml, and 3 others had a level above 500 ng/ml. The last patient was not tested.
  
  
  CONCLUSIONS
  The physician should be informed of the decrease of D-dimer under OAT, since the usual cut-off of 500 ng/ml used for deep vein thrombosis (DVT) exclusion is probably lower in such treated patients. It has been recently proposed that normal D-dimer level had a high negative predictive value for VTE recurrence when this dosage was performed 3 months after OAT interruption. The small number of recurrences observed in our study with an available result of D-dimer measured more than 3 months after OAT discontinuation does not allow a definite
authors.affiliation: Department of Biological Hematology, Hôtel Dieu Hospital, University of Paris, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Ombandza-Moussa
authors.forename: M M
authors.initials: MM
authors.lastname: Samama
authors.forename: M H
authors.initials: MH
authors.lastname: Horellou
authors.forename: I
authors.initials: I
authors.lastname: Elalamy
authors.forename: J
authors.initials: J
authors.lastname: Conard
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001774:Blood Chemical Analysis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013923:Thromboembolism / Q000097:blood* / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000097:blood* / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D